The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 2 – Asrar Qureshi’s Blog Post #1292

The Exit of Multinational Pharmaceutical Companies from Pakistan – Part 2 – Asrar Qureshi’s Blog Post #1292

Dear Colleagues! This is Asrar Qureshi’s Blog Post #1292 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here.

Credit: www.kaboompics.com

Preamble

This is Part 2 of a 3-part series about exit of multinational pharmaceutical companies from Pakistan market. It sets the historical context, documents the major multinational exits, and analyzes the structural reasons behind this trend.

Part 2 of a Three-Part Series

The Great Exit: What Happens When Multinational Pharmaceutical Companies Leave?

In Part 1 of this series, we examined why several multinational pharmaceutical companies (MNCs) have either exited Pakistan or significantly reduced their direct operations. We explored the commercial realities behind their decisions, like, price controls, currency depreciation, foreign exchange restrictions, global restructuring, and the growing strength of local pharmaceutical companies. However, corporate acquisitions and divestments are not merely financial transactions. They have consequences that ripple throughout the healthcare system.

When a research-based pharmaceutical company leaves a country, the impact extends far beyond its balance sheet. Doctors lose scientific partners, hospitals lose collaborators, employees face uncertainty, regulators lose valuable industry expertise, and patients may experience delayed access to innovative therapies.

The important question is not whether local companies can manufacture medicines; they undoubtedly can most medicines, though not all. The real question is whether the entire healthcare ecosystem remains equally strong when research-driven multinational companies gradually disappear. The answer is complex.

The Immediate Reality: Patients Do Not Lose Medicines Overnight

Whenever news breaks that a multinational pharmaceutical company is leaving Pakistan, the public reaction is usually one of concern. Will medicines disappear? Will patients suddenly be unable to obtain life-saving treatments? Fortunately, that has rarely been the case.

In most recent transactions, multinational companies have sold their brands, manufacturing facilities, and distribution networks to established Pakistani pharmaceutical companies. These local firms have continued producing and marketing many of the same medicines under existing brand names. For patients taking long-established medicines for hypertension, diabetes, antibiotics, gastrointestinal disorders, or cardiovascular diseases, there has generally been little immediate disruption. This demonstrates the remarkable maturity of Pakistan's domestic pharmaceutical industry. Yet continuity of supply is only one part of the equation.

Innovation Begins to Slow

The pharmaceutical industry operates on two parallel tracks.

The first is the manufacture of established medicines. The second is the discovery and introduction of new medicines. Local companies have become exceptionally good at the first. The second remains exclusively the domain of global research-based pharmaceutical companies.

Developing a single innovative medicine often requires more than a decade of research and investments exceeding billions of dollars. Only a relatively small number of multinational companies possess the scientific infrastructure needed for such research. When these companies reduce their presence in a country, that country automatically becomes a lower priority for launching innovative products.

The result is subtle but significant. Patients may eventually receive the latest therapies, but months or even years later than patients in larger or more commercially attractive markets. In rapidly evolving fields such as oncology, immunology, rare diseases, neurology, and advanced diabetes care, delayed access can have profound clinical consequences.

The Doctor's Perspective

Few professional groups feel the impact of multinational withdrawals more directly than physicians.

For decades, multinational pharmaceutical companies served not only as suppliers of medicines but also as important partners in medical education. Their medical affairs departments organized scientific symposia, invited internationally recognized experts, supported continuing medical education (CME), and facilitated access to the latest global clinical evidence.

These activities were not without controversy. Promotional practices rightly required ethical oversight, and regulators worldwide have strengthened governance around industry-physician relationships. Nevertheless, scientific exchange played an important role in keeping healthcare professionals informed about rapidly changing therapeutic advances. As multinational companies reduce their presence, opportunities for structured scientific engagement inevitably diminish.

Local companies have made commendable efforts to expand medical education activities, but their resources and global research networks are naturally more limited. The result may be fewer opportunities for Pakistani physicians to participate in international scientific dialogue.

Clinical Research Suffers

Perhaps the least discussed consequence is the impact on clinical research.

Global pharmaceutical companies conduct thousands of clinical trials every year. Participation in these studies offers multiple benefits:

• Patients gain early access to promising therapies.

• Physicians engage with cutting-edge science.

• Hospitals strengthen research capabilities.

• Young investigators develop research expertise.

• National regulatory systems gain experience evaluating innovative medicines.

Countries that host clinical trials also attract investment, develop specialized healthcare infrastructure, and strengthen academic medicine.

Unfortunately, Pakistan has historically participated in relatively few multinational clinical trials compared with neighboring countries such as India, China, and increasingly Vietnam. A shrinking multinational presence risks further reducing these opportunities. This represents a missed opportunity, not merely for the pharmaceutical industry but for Pakistan's scientific community as a whole.

The Human and Professional Impact

Corporate restructuring inevitably affects people. When multinational companies divest operations, employees often experience significant uncertainty. Even those who continue their careers with the acquiring Pakistani companies, must adapt to entirely new organizational cultures, reporting structures, and career paths.

Multinational companies have traditionally invested heavily in employee development. Their structured leadership programs, international training, compliance systems, medical education, and global career opportunities helped produce generations of highly skilled pharmaceutical professionals. Indeed, many senior executives leading Pakistan's largest domestic pharmaceutical companies today began their careers in multinational organizations.

As multinational participation declines, these developmental ecosystems become less extensive. Local companies now must carry the responsibility of developing the industry's future leadership, but they are falling short by a wide margin.

Can Local Companies Replace Global Innovation?

This question lies at the heart of the debate.

Manufacturing excellence and scientific innovation are not identical capabilities. Pakistan's leading pharmaceutical companies excel in producing high-quality branded generic medicines. However, discovering entirely new molecules requires research infrastructure of extraordinary scale. The average cost of bringing a new medicine from laboratory discovery to regulatory approval can exceed $2 billion, with only a small fraction of candidate molecules ever reaching patients. Such investments remain beyond the financial capacity of most pharmaceutical companies operating in developing economies.

Consequently, Pakistan will continue depending upon multinational innovators for breakthrough therapies in areas such as cancer, Alzheimer's disease, autoimmune disorders, gene therapies, rare diseases, advanced biologics, and precision medicine. If multinational engagement continues to decline, ensuring timely access to these innovations becomes increasingly challenging.

The Patient Experience

Ultimately, every discussion about the pharmaceutical industry must return to the patient.

Patients care less about corporate ownership than about drug availability and affordability.  In terms of established medicines, Pakistan's domestic industry has largely succeeded in maintaining availability. Affordability has often improved because local manufacturing reduces dependence on imported finished products. Quality standards among leading Pakistani manufacturers have also improved substantially over recent decades.

The greatest uncertainty concerns future innovation. Will Pakistani patients receive tomorrow's breakthrough medicines as quickly as patients elsewhere? Will new vaccines, biologics, and targeted therapies become available without significant delays? These questions deserve careful attention from policymakers.

A Balanced Perspective

It would be easy to portray multinational exits as an unmitigated disaster. That would be inaccurate. It would be equally misleading to suggest that nothing significant has changed. The reality lies between these extremes.

Pakistan's domestic pharmaceutical industry has matured impressively and has demonstrated that it can sustain manufacturing, preserve employment, and maintain medicine availability following major acquisitions. That is a considerable achievement.

At the same time, multinational pharmaceutical companies contribute much more than products. They bring scientific research, clinical trials, technology transfer, international collaboration, advanced medical education, and early access to innovation. These contributions are difficult to replace completely.

An ideal pharmaceutical ecosystem is therefore not one dominated exclusively by multinational companies or by domestic manufacturers. It is one where both flourish.

Pakistan's pharmaceutical industry now stands at an important crossroads. The remarkable growth of domestic companies demonstrates that local capability is no longer in question. The greater challenge is ensuring that Pakistan also remains an attractive destination for innovation, research, and international investment.

Part 2 Concluded.

Disclaimers: Pictures in these blogs are taken from free resources at Pexels, Pixabay, Unsplash, and Google. Credit is given where available. If a copyright claim is lodged, we shall remove the picture with appropriate regrets.

For most blogs, I research from several sources which are open to public. Their links are mentioned under references. There is no intent to infringe upon anyone’s copyrights. If, any claim is lodged, it will be acknowledged and duly recognized immediately.